摘要
目的 探讨炎症预后指数(IPI)联合外周血白细胞介素-11(IL-11)对晚期非小细胞肺癌(NSCLC)免疫相关不良反应(untoward reaction)的预测价值。方法 回顾性选择85例NSCLC患者临床资料。按是否发生ir AE分为发生ir AE组(n=26)和非ir AE组(n=59),收集患者临床资料,采用多因素Logistic回归分析IPI联合IL-11与NSCLC患者发生ir AE的关系,并进一步绘制ROC曲线分析IPI、IL-11单独及联合检测对NSCLC患者发生ir AE的预测价值。结果 两组CRP、IL-6、IL-11、LDH、NLR、PLR、IPI水平明显相关(P<0.05)。进一步分析显示,IL-11、LDH、IPI是影响NSCLC患者发生ir AE的独立危险因素。ROC曲线结果显示,IL-11、IPI单独检测预测NSCLC患者发生ir AE的曲线下面积分别为0.731、0.786(P<0.05)。两者联合检测的曲线下面积最大,为0.890(P<0.05)。结论 IPI联合IL-11水平用于预测NSCLC患者发生ir AE具有重要价值。
Objective To investigate the predictive value of inflammatory prognostic index(IPI)combined with peripheral blood interleukin-11(IL-11)for immune-related adverse reactions(irAE)in advanced non-small cell lung cancer(NSCLC).Methods The clinical data of 85 patients with NSCLC were retrospectively selected.According to the occurrence of irAE,the patients were divided into irAE group(n=26)and non-irAE group(n=59).The clinical data of patients were collected.Multivari-ate logistic regression was used to analyze the relationship between IPI combined with IL-1l and irAE in NSCLC patients.ROC curve was further drawn to analyze the predictive value of IPI,IL-11 alone and combined detection for irAE in NSCLC patients.Results The levels of CRP,IL-6,IL-11,LDH,NLR,PLR and IPI in the two groups were significantly corre-lated(P<0.05).Further analysis showed that IL-11,LDH and IPI were independent risk factors for irAE in NSCLC patients.ROC curve results showed that the area under the curve of IL-ll and IPI alone in predicting irAE in NSCLC patients was 0.731 and 0.786,respectively(P<0.05).The area under the curve of the combined detection was the largest,which was 0.890(P<0.05).Conclusion IPI combined with IL-11 level is of great value in predicting irAE in NSCLC patients.
作者
马宏武
吴伟璇
范浩钦
陈雪燕
Ma Hongwu;Wu Weixuan;Fan Haoqin;Chen Xueyan(Department of Oncology,Dafeng Hospital,Chaoyang District,Shantou 515154,China)
出处
《哈尔滨医药》
2023年第5期49-51,共3页
Harbin Medical Journal
关键词
炎症预后指数
非小细胞肺癌
白细胞介素-11
免疫相关不良反应
inflammatory prognostic index
non-small cell lung cancer
interleukin-ll
immune-related adverse reactions